|
CA2476934C
(en)
|
2002-02-27 |
2009-06-16 |
Immunex Corporation |
Stabilized tnfr-fc composition comprising arginine
|
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
|
EP1877438A2
(en)
|
2005-02-02 |
2008-01-16 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
CA3142945A1
(en)
|
2005-03-25 |
2006-10-05 |
Regeneron Pharmaceuticals, Inc. |
Histidine-buffered formulations of vegf antagonist
|
|
JP2008543839A
(ja)
|
2005-06-14 |
2008-12-04 |
アムジェン インコーポレーテッド |
自己緩衝タンパク質製剤
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
CN103816115B
(zh)
|
2010-08-31 |
2017-06-27 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
AU2012340107B2
(en)
|
2011-11-18 |
2017-06-15 |
Regeneron Pharmaceuticals, Inc. |
Polymer protein microparticles
|
|
WO2013096221A1
(en)
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
CN107115294B
(zh)
|
2012-01-19 |
2019-10-18 |
北京康弘生物医药有限公司 |
一种含有vegf拮抗剂的滴眼液
|
|
US20130323242A1
(en)
*
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
|
JP2015519373A
(ja)
|
2012-06-01 |
2015-07-09 |
オプソテック コーポレイションOphthotech Corporation |
抗pdgfアプタマーおよびvegf拮抗薬を含む組成物
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
WO2014078627A1
(en)
|
2012-11-19 |
2014-05-22 |
Merck Sharp & Dohme Corp. |
Liquid formulations for tnfr:fc fusion proteins
|
|
MX377714B
(es)
|
2013-10-18 |
2025-03-11 |
Regeneron Pharma |
Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
|
|
CN105435222B
(zh)
|
2014-09-25 |
2018-05-29 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
MX390837B
(es)
|
2015-10-16 |
2025-03-21 |
Regeneron Pharma |
Composiciones de proteinas estables.
|
|
MY200764A
(en)
*
|
2015-12-16 |
2024-01-14 |
Regeneron Pharma |
Compositions and methods of manufacturing protein microparticles
|
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
|
WO2017168296A1
(en)
|
2016-03-29 |
2017-10-05 |
Navya Biologicals Pvt. Ltd |
A process for purification of fc-fusion proteins
|
|
KR101685532B1
(ko)
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
WO2018063963A1
(en)
|
2016-09-28 |
2018-04-05 |
Board Of Regents, The University Of Texas System |
Antibody and protein therapeutic formulations and uses thereof
|
|
ES3064802T3
(en)
|
2016-10-21 |
2026-04-29 |
Amgen Inc |
Pharmaceutical formulations and methods of making the same
|
|
CN109937034B
(zh)
|
2016-11-21 |
2022-09-16 |
济世-伊沃泰克生物制品有限公司 |
阿柏西普制剂及其用途
|
|
BR112019011900A2
(pt)
|
2016-12-23 |
2019-11-26 |
Serum Institute Of India Private Limited |
métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
|
|
KR101861163B1
(ko)
*
|
2017-04-26 |
2018-05-25 |
삼천당제약주식회사 |
안과용 약학 조성물
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
US20200255496A1
(en)
|
2017-09-18 |
2020-08-13 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
CN107595765A
(zh)
|
2017-09-22 |
2018-01-19 |
沈阳兴齐眼药股份有限公司 |
一种眼用缓释药物递送系统及其制备方法
|
|
WO2019099921A2
(en)
|
2017-11-17 |
2019-05-23 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
MY202872A
(en)
|
2017-11-20 |
2024-05-28 |
Just Evotec Biologics Inc |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
EP3730126B1
(en)
|
2017-12-22 |
2025-05-14 |
Samsung Bioepis Co., Ltd. |
Liquid composition comprising vegf antagonist
|
|
WO2019173767A1
(en)
*
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
RS67656B1
(sr)
|
2018-05-10 |
2026-02-27 |
Regeneron Pharma |
Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
|
|
WO2020055123A1
(ko)
|
2018-09-10 |
2020-03-19 |
삼성바이오에피스 주식회사 |
단백질을 포함하는 액상 조성물
|
|
US20210353713A1
(en)
|
2018-10-26 |
2021-11-18 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
EP3923907B1
(en)
|
2019-02-13 |
2024-09-25 |
Novaliq GmbH |
Compositions and methods for the treatment of ocular neovascularization
|
|
GB201911461D0
(en)
|
2019-08-09 |
2019-09-25 |
Arecor Ltd |
Novel composition
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|